Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma

Razumilava, 2014, Cholangiocarcinoma, Lancet, 383, 2168, 10.1016/S0140-6736(13)61903-0 Rizvi, 2018, Cholangiocarcinoma - evolving concepts and therapeutic strategies, Nat Rev Clin Oncol, 15, 95, 10.1038/nrclinonc.2017.157 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721 Oh, 2022, Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer, NEJM Evid, 1, 10.1056/EVIDoa2200015 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol, 21, 671, 10.1016/S1470-2045(20)30109-1 Abou-Alfa, 2020, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 21, 796, 10.1016/S1470-2045(20)30157-1 FDA grants accelerated approval to futibatinib for cholangiocarcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma. Accessed 30 Sep 2022. Diggs, 2021, CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma, J Hepatol, 74, 1145, 10.1016/j.jhep.2020.11.037 Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 Fan, 2012, Cholangiocarcinomas can originate from hepatocytes in mice, J Clin Invest, 122, 2911, 10.1172/JCI63212 Vijgen, 2017, Pathology of intrahepatic cholangiocarcinoma, Hepatobiliary Surg Nutr, 6, 22, 10.21037/hbsn.2016.11.04 Farshidfar, 2017, Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles, Cell Rep, 18, 2780, 10.1016/j.celrep.2017.02.033 Zhang, 2020, Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma, J Hepatol, 73, 1118, 10.1016/j.jhep.2020.05.039 Ma, 2019, Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer, Cancer cell, 36, 418, 10.1016/j.ccell.2019.08.007 Jenne, 2013, Immune surveillance by the liver, Nat Immunol, 14, 996, 10.1038/ni.2691 Ringelhan, 2018, The immunology of hepatocellular carcinoma, Nat Immunol, 19, 222, 10.1038/s41590-018-0044-z Yu, 2021, Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination, Nat Med, 27, 152, 10.1038/s41591-020-1131-x Job, 2020, Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma, Hepatology, 72, 965, 10.1002/hep.31092 Raskov, 2021, Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy, Br J Cancer, 124, 359, 10.1038/s41416-020-01048-4 O'Donnell, 2019, Cancer immunoediting and resistance to T cell-based immunotherapy, Nat Rev Clin Oncol, 16, 151, 10.1038/s41571-018-0142-8 Vigano, 2019, Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular carcinoma. Impact on prognosis after complete Surgery, J Gastrointest Surg : official J Soc Surg Aliment Tract, 23, 2216, 10.1007/s11605-019-04111-5 Kobayashi, 2007, FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis, Clin Cancer Res : official J Am Assoc Cancer Res, 13, 902, 10.1158/1078-0432.CCR-06-2363 Greene, 2017, MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates, Mucosal Immunol, 10, 802, 10.1038/mi.2016.91 Zimmer, 2022, Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma, Hepatology, 75, 1154, 10.1002/hep.32222 Schrumpf, 2015, The biliary epithelium presents antigens to and activates natural killer T cells, Hepatology, 62, 1249, 10.1002/hep.27840 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331 Ye, 2009, Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion, J Surg Oncol, 100, 500, 10.1002/jso.21376 Deng, 2021, Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients, Cancer Cell Int, 21, 371, 10.1186/s12935-021-02081-w Asahi, 2020, Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma, Surg Today, 50, 931, 10.1007/s00595-020-01967-y Sabbatino, 2016, PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma, Clin Cancer Res : official J Am Assoc Cancer Res, 22, 470, 10.1158/1078-0432.CCR-15-0715 Zhou, 2019, Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules, J Hepatol, 71, 753, 10.1016/j.jhep.2019.05.026 Zhou, 2021, Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target, EBioMedicine, 67, 10.1016/j.ebiom.2021.103375 Raggi, 2017, Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages, J Hepatol, 66, 102, 10.1016/j.jhep.2016.08.012 Hasita, 2010, Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma, Cancer Sci, 101, 1913, 10.1111/j.1349-7006.2010.01614.x Tamma, 2019, Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma, Eur J Clin Invest, 49, 10.1111/eci.13087 Boulter, 2015, WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited, J Clin Invest, 125, 1269, 10.1172/JCI76452 Loeuillard, 2020, Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma, J Clin Invest, 130, 5380, 10.1172/JCI137110 Lin, 2019, Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment, Neoplasia, 21, 1133, 10.1016/j.neo.2019.10.005 Zhang, 2021, Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma, Cancer Discov, 11, 1248, 10.1158/2159-8290.CD-20-0304 Fukuda, 2020, Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma, Cancer Sci, 111, 323, 10.1111/cas.14267 Oliviero, 2022, MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma, Oncoimmunology, 11, 10.1080/2162402X.2022.2035919 Gu, 2012, Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 19, 2506, 10.1245/s10434-012-2268-8 Wang, 2018, Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer, Cancer Sci, 109, 2266, 10.1111/cas.13627 Zhou, 2014, CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils, Carcinogenesis, 35, 597, 10.1093/carcin/bgt397 MacParland, 2018, Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations, Nat Commun, 9, 4383, 10.1038/s41467-018-06318-7 Aizarani, 2019, A human liver cell atlas reveals heterogeneity and epithelial progenitors, Nature, 572, 199, 10.1038/s41586-019-1373-2 Kwon, 2019, Functional genomic complexity defines intratumor heterogeneity and tumor aggressiveness in liver cancer, Scientific Rep, 9 Alvisi, 2022, Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target, J Hepatol, 77, 1359, 10.1016/j.jhep.2022.05.043 Zheng, 2017, Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing, Cell, 169, 1342, 10.1016/j.cell.2017.05.035 Xue, 2022, Liver tumour immune microenvironment subtypes and neutrophil heterogeneity, Nature, 612, 141, 10.1038/s41586-022-05400-x Wongkajornsilp, 2009, Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice, Cancer Invest, 27, 140, 10.1080/07357900802189832 Morisaki, 2012, Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro, Anticancer Res, 32, 2249 Noda, 2012, Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma, Hepatology, 55, 86, 10.1002/hep.24629 Panya, 2018, Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells, Cancer Immunol Immunother : CII, 67, 1579, 10.1007/s00262-018-2212-2 Thepmalee, 2018, Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells, Hum Vaccin Immunother, 14, 1423, 10.1080/21645515.2018.1431598 Yamada, 2015, IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism, Hepatology, 61, 1627, 10.1002/hep.27687 Wang, 2019, Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis, J Hepatol, 71, 742, 10.1016/j.jhep.2019.05.027 Lu, 2021, YAP accelerates notch-driven cholangiocarcinogenesis via mTORC1 in mice, Am J Pathol, 191, 1651, 10.1016/j.ajpath.2021.05.017 Ruffolo, 2022, GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity, Gut, 71, 1386, 10.1136/gutjnl-2021-324109 Ushach, 2016, Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage, J Leukoc Biol, 100, 481, 10.1189/jlb.3RU0316-144R Kam, 2021, Current and emerging therapies for advanced biliary tract cancers, Lancet Gastroenterol Hepatol, 6, 956, 10.1016/S2468-1253(21)00171-0 Wabitsch, 2021, Anti-PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in mice, Cell Mol Gastroenterol Hepatol, 12, 1166, 10.1016/j.jcmgh.2021.05.011 Kobayashi, 2013, Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer, J Gastrointest Surg : official J Soc Surg Aliment Tract, 17, 1609, 10.1007/s11605-013-2286-2 Feng, 2017, Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma, J Hematol Oncol, 10, 4, 10.1186/s13045-016-0378-7 Alnaggar, 2019, Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma, J Immunother Cancer, 7, 36, 10.1186/s40425-019-0501-8 Shimizu, 2012, Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma, J hepato-biliary-pancreatic Sci, 19, 171, 10.1007/s00534-011-0437-y Wells, 2020, Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction, Cell, 183, 818, 10.1016/j.cell.2020.09.015 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Riviere, 2020, High tumor mutational burden correlates with longer survival in immunotherapy-naive patients with diverse cancers, Mol Cancer Ther, 19, 2139, 10.1158/1535-7163.MCT-20-0161 Lu, 2021, DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity, Cancer Cell, 39, 96, 10.1016/j.ccell.2020.11.006 Nakamura, 2015, Genomic spectra of biliary tract cancer, Nat Genet, 47, 1003, 10.1038/ng.3375 Weinberg, 2019, Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets, J Gastrointest Oncol, 10, 652, 10.21037/jgo.2018.08.18 Gbolahan, 2019, Prolonged response to anti-PD-1 antibody therapy in chemotherapy-refractory cholangiocarcinoma with high tumor mutational burden, J Natl Compr Canc Netw, 17, 644, 10.6004/jnccn.2019.7304 Mou, 2018, Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report, BMC cancer, 18, 1105, 10.1186/s12885-018-5021-2 Sui, 2019, Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade, J Immunother Cancer, 7, 125, 10.1186/s40425-019-0596-y Czink, 2017, Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer, Cold Spring Harbor Mol case Stud, 3 Eguchi, 2021, Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report, Clin J Gastroenterol, 14, 858, 10.1007/s12328-021-01396-5 Ikeda, 2021, Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: a case report, Clin case Rep, 9, 2259, 10.1002/ccr3.4008 Kai, 2021, Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer, JGH open : open access J Gastroenterol Hepatol, 5, 712, 10.1002/jgh3.12576 Toshida, 2021, Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report, Clin J Gastroenterol, 14, 1459, 10.1007/s12328-021-01458-8 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105 Kim, 2020, A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer, JAMA Oncol, 6, 888, 10.1001/jamaoncol.2020.0930 Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, 17, e542, 10.1016/S1470-2045(16)30406-5 Fontugne, 2017, PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma, Oncotarget, 8, 24644, 10.18632/oncotarget.15602 Piha-Paul, 2020, Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies, Int J Cancer, 147, 2190, 10.1002/ijc.33013 Ott, 2019, T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: keynote-028, J Clin Oncol, 37, 318, 10.1200/JCO.2018.78.2276 Koido, 2014, Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy, Anticancer Res, 34, 6353 Liu, 2010, Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses, Br J Cancer, 102, 115, 10.1038/sj.bjc.6605465 Homma, 2014, Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer, Clin Transl Oncol, 16, 330, 10.1007/s12094-013-1079-0 Feng, 2020, Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study, J Immunother Cancer, 8 Ueno, 2019, Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study, Lancet Gastroenterol Hepatol, 4, 611, 10.1016/S2468-1253(19)30086-X Klein, 2020, Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial, JAMA Oncol, 6, 1405, 10.1001/jamaoncol.2020.2814 Ioka, 2019, Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC), J Clin Oncol, 37, 387, 10.1200/JCO.2019.37.4_suppl.387 Boileve, 2021, Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial, Eur J Cancer, 143, 55, 10.1016/j.ejca.2020.10.027 Chen, 2021, Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial, Int J Cancer, 149, 1944, 10.1002/ijc.33751 Chen, 2020, Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial, J Immunother Cancer, 8 Gou, 2021, PD-1 inhibitors could improve the efficacy of chemotherapy as first-line treatment in biliary tract cancers: a propensity score matching based analysis, Front Oncol, 11, 10.3389/fonc.2021.648068 Banales, 2020, Cholangiocarcinoma 2020: the next horizon in mechanisms and management, Nat Rev Gastroenterol Hepatol, 17, 557, 10.1038/s41575-020-0310-z Massa, 2020, Evolution of the experimental models of cholangiocarcinoma, Cancers (Basel), 12, 10.3390/cancers12082308 Tian, 2020, PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome, World J Surg Oncol, 18, 303, 10.1186/s12957-020-02082-5 Arkenau, 2018, Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF), Oncologist, 23, 1407-e136, 10.1634/theoncologist.2018-0044 Yoo, 2020, Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer, J Immunother Cancer, 8 Monge, 2022, A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma, The oncologist, 27, e273, 10.1093/oncolo/oyab073 Mei, 2021, Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial, J Immunother Cancer, 9 Oh, 2022, Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study, Lancet Gastroenterol Hepatol, 7, 522, 10.1016/S2468-1253(22)00043-7 Wang, 2021, The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study, Front Oncol, 11 Yarchoan, 2021, Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers, J Clin Invest, 131, 10.1172/JCI152670 Xie, 2019, Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer, Hepatology, 69, 2048, 10.1002/hep.30482